AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9040911 — intervention group
Group type: COMPARATOR
Intervention: No modifications at University of Montreal (UM) (control group)
Number of subjects: 57
Study 8176256 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg taken each morning for 6 days before cyclosporin doses
Number of subjects: 20
Study 8176256 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin 300 mg taken alone
Number of subjects: 20
Study 8176256 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg taken on the seventh day with cyclosporin
Number of subjects: 20
Study 8176256 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg taken with cyclosporin
Number of subjects: 20
Study 3579464 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (0.5 mg/kg/d)
Number of subjects: 19
Study 3579464 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 controls)
Number of subjects: 19
Study 30445454 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief incubation (0.3-1.2 million motile sperm/ml for 3-4 hours)
Number of subjects: 320
Study 30445454 — intervention group
Group type: COMPARATOR
Intervention: Standard incubation (0.3-1.2 million motile sperm/ml for 20 hours)
Number of subjects: 320
Study 30445454 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief incubation
Number of subjects: 320
Study 30445454 — intervention group
Group type: COMPARATOR
Intervention: Standard incubation
Number of subjects: 320
Study 30445454 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 320
Study 28581367 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 12
Study 28581367 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 12
Study 28581367 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 12
Study 25895588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25895588 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg + modified release nifedipine 30 mg
Number of subjects: 100
Study 25154152 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol followed by 3 tablets of 200 microg misoprostol
Number of subjects: 150
Study 25154152 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 tablets)
Number of subjects: 150
Study 22484899 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaFlow
Number of subjects: 10
Study 22484899 — intervention group
Group type: COMPARATOR
Intervention: Zinc-oxide eugenol sealer and gutta-percha cone using cold lateral obturation technique
Number of subjects: 10
Study 19835463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 587
Study 19835463 — intervention group
Group type: COMPARATOR
Intervention: Control (oral glucose-lowering drugs excluding thiazolidinediones)
Number of subjects: 587
Study 19835463 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 587
Study 17093249 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation
Number of subjects: 40
Study 17093249 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study 17093249 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurostimulation (after 6 months of active treatment)
Number of subjects: 40
Study 15243006 — intervention group
Group type: EXPERIMENTAL
Intervention: FF-MAS 5 microM
Number of subjects: 243
Study 15243006 — intervention group
Group type: EXPERIMENTAL
Intervention: FF-MAS 20 microM
Number of subjects: 243
Study 15243006 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 0.2% (vehicle control)
Number of subjects: 243
Study 15243006 — intervention group
Group type: COMPARATOR
Intervention: Water for injection (inert control)
Number of subjects: 243
Study 12821971 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g CLA per day (low dosage, LD)
Number of subjects: 54
Study 12821971 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g CLA per day (high dosage, HD)
Number of subjects: 54
Study 12821971 — intervention group
Group type: COMPARATOR
Intervention: Placebo LD
Number of subjects: 54
Study 12821971 — intervention group
Group type: COMPARATOR
Intervention: Placebo HD
Number of subjects: 54
Study 10225800 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoprene sleeve
Number of subjects: 119
Study 10225800 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloader brace
Number of subjects: 119
Study 10225800 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study 7782190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DOTA
Number of subjects: 1038
Study 7782190 — intervention group
Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 1038
Study 1976680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential use of unmedicated soap (3 min) followed by 'Hibisol' (4 min)
Number of subjects: 0
Study 1976680 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of 'Hibiscrub' (3 min) and 'Hibisol' (4 min)
Number of subjects: 0
Study 1976680 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of 'Hibisol' for 5 min
Number of subjects: 0
Study 1976680 — intervention group
Group type: COMPARATOR
Intervention: Reference procedure with 60% n‐propanol (5 min)
Number of subjects: 0
Study 639614 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal dilatation
Number of subjects: 66
Study 639614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincterotomy
Number of subjects: 66
Study 31164158 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and self-management group behavioural intervention
Number of subjects: 0
Study 31164158 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidelity assessment through audio recordings
Number of subjects: 0
Study 29048969 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Depression Awareness Program (ADAP; n=3681)
Number of subjects: 6679
Study 29048969 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition (n=2998)
Number of subjects: 6679
Study 26992237 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% caloric restriction (CR)
Number of subjects: 0
Study 26992237 — intervention group
Group type: COMPARATOR
Intervention: Ad-Libitum intake (AL)
Number of subjects: 0
Study 25141241 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 651
Study 25141241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 651
Study 22542608 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 deficiency assessment via Functional Intracellular Assay (FIA)
Number of subjects: 22
Study 22542608 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and gender-matched)
Number of subjects: 22
Study 19091408 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III RCTs
Number of subjects: 36
Study 19091408 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab interventional case studies
Number of subjects: 36
Study 19091408 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab studies
Number of subjects: 36
Study 17468463 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI education
Number of subjects: 30164
Study 17468463 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI education (for those visiting Nantucket Island for more than 2 weeks)
Number of subjects: 30164
Study 17468463 — intervention group
Group type: COMPARATOR
Intervention: Bicycle safety education
Number of subjects: 30164
Study 15249406 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed, humidified CO2 insufflation (group B)
Number of subjects: 101
Study 15249406 — intervention group
Group type: COMPARATOR
Intervention: Standard CO2 insufflation (group A)
Number of subjects: 101
Study 12028405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 150 mg daily for four weeks
Number of subjects: 0
Study 9820260 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Chinese herbal formulations (n = 38)
Number of subjects: 116
Study 9820260 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Chinese herbal formulation (n = 43)
Number of subjects: 116
Study 9820260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 35)
Number of subjects: 116
Study 9820260 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active treatment groups (individualized and standard CHM)
Number of subjects: 116
Study 7715792 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 400
Study 29188483 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-irradiation treatment schedules
Number of subjects: 375
Study 26873702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Number of subjects: 1
Study 26873702 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with dabrafenib (plus placebo)
Number of subjects: 1
Study 24744318 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-fortified salt (DFS) with 3.3 mg ferrous fumarate (1.1 mg elemental iron) per kg of iodized salt for 7.5 to 9 months
Number of subjects: 212
Study 24744318 — intervention group
Group type: COMPARATOR
Intervention: Control iodized salt (47 mg/kg potassium iodate) for 7.5 to 9 months
Number of subjects: 212
Study 23677749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation treatment consisting of 16 one-hour individual sessions of therapist-guided cognitive training over 4 weeks, combining computer exercises and metacognitive training.
Number of subjects: 109
Study 23677749 — intervention group
Group type: COMPARATOR
Intervention: Usual care without cognitive training (Control group).
Number of subjects: 109
Study 20033244 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable tablet containing calcium and vitamin D (Calci Chew D(3), Nycomed)
Number of subjects: 102
Study 20033244 — intervention group
Group type: COMPARATOR
Intervention: Sachet containing calcium and vitamin D(3) (Cad, Will‐Pharma)
Number of subjects: 102
Study 20033244 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 102
Study 18256175 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazax (ALK‐Abelló) for sublingual immunotherapy
Number of subjects: 0
Study 18256175 — intervention group
Group type: COMPARATOR
Intervention: Intranasal corticosteroids and oral antihistamines
Number of subjects: 0
Study 16527695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide tablets (500 mg, twice daily for 3 days)
Number of subjects: 90
Study 16527695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide oral suspension (500 mg, twice daily for 3 days)
Number of subjects: 90
Study 16527695 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching tablet, twice daily for 3 days)
Number of subjects: 90
Study 14505071 — intervention group
Group type: EXPERIMENTAL
Intervention: Z250
Number of subjects: 150
Study 14505071 — intervention group
Group type: COMPARATOR
Intervention: Z100
Number of subjects: 150
Study 10743981 — intervention group
Group type: EXPERIMENTAL
Intervention: Humalog Mix75/25
Number of subjects: 84
Study 10743981 — intervention group
Group type: COMPARATOR
Intervention: Human insulin 70/30
Number of subjects: 84
Study 8755321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral human recombinant epidermal growth factor (450 mg/day)
Number of subjects: 75
Study 8755321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral human recombinant epidermal growth factor (600 mg/day)
Number of subjects: 75
Study 8755321 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 75
Study 1407989 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole alone (150 mg/day for 3 consecutive days)
Number of subjects: 39
Study 1407989 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole in combination with prednisone (150 mg/day for 3 consecutive days)
Number of subjects: 39
Study 1407989 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (alone or in combination with prednisone)
Number of subjects: 39
Study 4008417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (3 cigarettes/h for 5 h)
Number of subjects: 9
Study 4008417 — intervention group
Group type: COMPARATOR
Intervention: Control (no smoking)
Number of subjects: 9
Study 29100198 — intervention group
Group type: EXPERIMENTAL
Intervention: sucking + breast milk
Number of subjects: 109
Study 29100198 — intervention group
Group type: EXPERIMENTAL
Intervention: sucking + breast milk + tucking
Number of subjects: 109
Study 29100198 — intervention group
Group type: COMPARATOR
Intervention: routine care
Number of subjects: 109
Study 28414474 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence Incentives plus weekly behavioral parent training (EXP)
Number of subjects: 75
Study 28414474 — intervention group
Group type: COMPARATOR
Intervention: Attendance Incentives (CONTROL)
Number of subjects: 75
Study 26122834 — intervention group
Group type: EXPERIMENTAL
Intervention: pUDK-HGF (4-16 mg)
Number of subjects: 21
Study 23851746 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 20
Study 23851746 — intervention group
Group type: COMPARATOR
Intervention: Control (blood clot)
Number of subjects: 20
Study 20864308 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 299
Study 20864308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 18230858 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast ForWord Language (FFW‐L)
Number of subjects: 216
Study 18230858 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted language intervention (CALI)
Number of subjects: 216
Study 18230858 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized language intervention (ILI)
Number of subjects: 216
Study 18230858 — intervention group
Group type: COMPARATOR
Intervention: Academic enrichment (AE)
Number of subjects: 216
Study 18230858 — intervention group
Group type: COMPARATOR
Intervention: All conditions (FFW‐L, AE, CALI, ILI)
Number of subjects: 216
Study 15692611 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyetrack
Number of subjects: 20
Study 15692611 — intervention group
Group type: COMPARATOR
Intervention: CPR
Number of subjects: 20
Study 15692611 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyetrack (expert user)
Number of subjects: 20
Study 12949382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea intake (mean daily intake 525 mL)
Number of subjects: 218
Study 12949382 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-O-methylgallic acid excretion (biomarker of tea-derived polyphenols)
Number of subjects: 218
Study 10958582 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body shots in colour or monochrome (Expt 1)
Number of subjects: 80
Study 10958582 — intervention group
Group type: EXPERIMENTAL
Intervention: Close-up pictures of targets' faces (Expt 2)
Number of subjects: 80
Study 9275324 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory strengthening training programs
Number of subjects: 24
Study 9275324 — intervention group
Group type: COMPARATOR
Intervention: Routine physical exercises (Control)
Number of subjects: 24
Study 1892491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine taken with food
Number of subjects: 10
Study 1892491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine taken before food
Number of subjects: 10
Study 6441716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral potassium supplementation during protein-modified fast
Number of subjects: 0
Study 6441716 — intervention group
Group type: COMPARATOR
Intervention: Protein-modified fast without potassium supplementation
Number of subjects: 0
Study 31151820 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual nutritional assessment
Number of subjects: 170
Study 31151820 — intervention group
Group type: COMPARATOR
Intervention: Standardized enteral nutrition
Number of subjects: 170
Study 31151820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 170
Study 28414493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126
Study 26607845 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agent (ESA; darbepoetin-α) treatment
Number of subjects: 35
Study 26607845 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 35
Study 26607845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ESA treatment and endurance training
Number of subjects: 35
Study 24739510 — intervention group
Group type: COMPARATOR
Intervention: DynaClose tissue expansion tapes applied across the forearm one week pre-operatively.
Number of subjects: 24
Study 23149692 — intervention group
Group type: EXPERIMENTAL
Intervention: Webcams with a central monitoring system and virtual bed rail function for patients with a Morse Risk Assessment (MRA) score greater than 25.
Number of subjects: 10
Study 23149692 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Webcams).
Number of subjects: 10
Study 20613670 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day for 6 months
Number of subjects: 70
Study 20613670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medications)
Number of subjects: 70
Study 18167048 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar cane policosanol 20 mg daily for 8 weeks
Number of subjects: 68
Study 18167048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 16359632 — intervention group
Group type: EXPERIMENTAL
Intervention: High cross-modal dissimilarity textures
Number of subjects: 0
Study 16359632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cross-modal dissimilarity textures
Number of subjects: 0
Study 15320669 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (7 mg.kg(‐1) of body weight)
Number of subjects: 10
Study 15320669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin C, same dosage as caffeine)
Number of subjects: 10
Study 11207403 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-min infusion of prochlorperazine (10 mg) followed by a 15-min infusion of saline
Number of subjects: 160
Study 11207403 — intervention group
Group type: COMPARATOR
Intervention: 15-min infusion of prochlorperazine (10 mg) following a 2-min infusion of saline
Number of subjects: 160
Study 9308800 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone alone or naltrexone in combination with an anti-oestrogen
Number of subjects: 22
Study 9308800 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophin induction of ovulation
Number of subjects: 22
Study 8233386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin 0.2 mg
Number of subjects: 11
Study 8233386 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin 0.02 mg
Number of subjects: 11
Study 3658353 — intervention group
Group type: COMPARATOR
Intervention: Aqueous phenylephrine hydrochloride (2.5%) in 32 microliters drop volume
Number of subjects: 10
Study 3658353 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% aqueous phenylephrine in 8 microliters drop volume
Number of subjects: 10
Study 3658353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations (2.5% in 32 microliters and 10% in 8 microliters)
Number of subjects: 10
Study 30337343 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk by Faith (WbF) - monthly diet and exercise education sessions
Number of subjects: 0
Study 30337343 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk by Faith (WbF) - men
Number of subjects: 0
Study 30337343 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk by Faith (WbF) - married women
Number of subjects: 0
Study 30337343 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk by Faith (WbF) - unmarried women
Number of subjects: 0
Study 30337343 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk by Faith (WbF) - participation level
Number of subjects: 0
Study 30337343 — intervention group
Group type: COMPARATOR
Intervention: Ribbons of Faith (RoF) - educational program
Number of subjects: 0
Study 27188744 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU once
Number of subjects: 123
Study 27188744 — intervention group
Group type: COMPARATOR
Intervention: halcinonide for 3 months
Number of subjects: 123
Study 25300977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 130
Study 25300977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 22614993 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 472
Study 22614993 — intervention group
Group type: COMPARATOR
Intervention: Printed educational information
Number of subjects: 472
Study 20980648 — intervention group
Group type: COMPARATOR
Intervention: 25% milk RUTF
Number of subjects: 1874
Study 20980648 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% milk RUTF
Number of subjects: 1874
Study 18600190 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine (Priorix-Tetra; GlaxoSmithKline Biologicals) - 2 doses administered 42 days apart (MMRV group; N = 732)
Number of subjects: 970
Study 18600190 — intervention group
Group type: COMPARATOR
Intervention: MMR vaccine (Priorix) coadministered with varicella vaccine (Varilrix) - 1 dose followed by a second dose of MMR vaccine 42 days later (MMR + V group; N = 238)
Number of subjects: 970
Study 16204741 — intervention group
Group type: EXPERIMENTAL
Intervention: StarClose Vascular Closure System
Number of subjects: 208
Study 16204741 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 208
Study 12084751 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet group (written educational material)
Number of subjects: 0
Study 12084751 — intervention group
Group type: COMPARATOR
Intervention: Control group (no written information)
Number of subjects: 0
Study 10596687 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg budesonide + 24 microg formoterol (Bud800+F)
Number of subjects: 470
Study 10596687 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide + 24 microg formoterol (Bud200+F)
Number of subjects: 470
Study 10596687 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,600 microg budesonide (run-in phase)
Number of subjects: 470
Study 10596687 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg budesonide + placebo
Number of subjects: 470
Study 10596687 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide + placebo
Number of subjects: 470
Study 8706453 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic positive airway pressure ventilation
Number of subjects: 20